返回
Shanghai Henlius Biotech, Inc.（02696.HK）價格
02696.HK 股價走勢圖
HENLIUS (02696.HK)
Shanghai Henlius Biotech, Inc.
HK$0
0%
$0
盤中： Jan 30, 11:27:18 HKT
暫無資料Earnings FAQ
02696.HK 最近的每股盈餘與預期相比如何？
Shanghai Henlius Biotech, Inc. 02696.HK 上一季度的收入表現如何？
Shanghai Henlius Biotech, Inc. 的收入預期是多少？
Shanghai Henlius Biotech, Inc. 的盈利品質評分是多少？
Shanghai Henlius Biotech, Inc. 何時發布財報？
Shanghai Henlius Biotech, Inc. 的預期收益是多少？
Shanghai Henlius Biotech, Inc. 是否超出收益預期？
關鍵數據
前收市價
--
開盤價
--
當日範圍
-
52週區間
-
交易量
--
平均成交量
1.1M
每股盈餘 (TTM)
1.68
股息收益率
--
市值
--
什麼是 HENLIUS？
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.